logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
A

Alexander Schuhmacher

Technische Hochschule Ingolstadt

18H指数
68论文数
1.2K被引数
收录论文 30
发表时间
logo
Reassessing R&D outcomes of leading pharmaceutical companies重新评估领先制药公司的研发成果
errDrug Discovery Today
IF7.5
err2026-08-11
err0
errOAAI
errAlexander Schuhmacher; Michael Witting; Dominik Hartl; Markus Hinder; Oliver Gassmann
err分享
err收藏
New perspectives for better R&D performance: lessons learned from leading pharma companies提升研发绩效的新视角：来自领先制药公司的经验教训
errDrug Discovery Today
IF7.5
err2026-04-17
err0
errOAAI
errAlexander Schuhmacher; Oliver Gassmann; Sara Knapp; Dominik Hartl; Markus Hinder
err分享
err收藏
The R&D productivity challenge: transforming the pharmaceutical ecosystem研发生产力挑战：变革制药生态系统
errDrug Discovery Today
IF7.5
err2025-10-09
err0
errOAAI
errAlexander Schuhmacher; Oliver Gassmann; Sebastian Kwisda; Malte Kremer; Markus Hinder; Dominik Hartl
err分享
err收藏
The Role of Data Monitoring Committees in drug research数据监查委员会在药物研究中的作用
errDrug Discovery Today
IF7.5
err2025-09-18
err0
PREAI
errMarkus Hinder; Nandhini Madesh; Dominik Hartl; Alexander Schuhmacher
err分享
err收藏
Does pharma R&D need a strategic reset? Adapting to a changing US landscape制药研发是否需要战略重置？适应变化的美国格局
errDrug Discovery Today
IF7.5
err2025-07-28
err0
errOAAI
errSebastian Kwisda; Malte Kremer; Niels Sievertsen; Oliver Gassmann; Dominik Hartl; Alexander Schuhmacher
err分享
err收藏
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022) (vol 30, 104291, 2025)对领先制药公司研发成功率进行基准测试：一项关于FDA批准（2006-2022年）的实证分析（卷30，104291，2025）
errDRUG DISCOVERY TODAY
IF7.5
err2025-05-01
err0
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Brief, Elazar; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies
errDRUG DISCOVERY TODAY
IF7.5
err2025-03-01
err0
errOAAI
errSchuhmacher, Alexander; Grinchenko, Kyrylo; Gassmann, Oliver; Hartl, Dominik; Hinder, Markus
err分享
err收藏
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)
errDRUG DISCOVERY TODAY
IF7.5
err2025-02-01
err0
errOAAI
errSchuhmacher, Alexander; Hinder, Markus; Brief, Elazar; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
Pharma innovation: how evolutionary economics is shaping the future of pharma R&D
errDRUG DISCOVERY TODAY
IF7.5
err2024-12-01
err0
errOAAI
errSchuhmacher, Alexander
err分享
err收藏
Exploring open source as a strategy to enhance R&D productivity
errEXPERT OPINION ON DRUG DISCOVERY
IF4.9
err2024-10-15
err0
errOAAI
errSchuhmacher, Alexander
err分享
err收藏
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023)前20家制药公司FDA批准的比较分析 (2014-2023)
errDRUG DISCOVERY TODAY
IF7.5
err2024-09-01
err2
errOAAI
errSchuhmacher, Alexander; Gassmann, Oliver; Hinder, Markus; Hartl, Dominik
err分享
err收藏
Pre-clinical evaluation of advanced nerve guide conduits using a novel 3D in vitro testing model
errINTERNATIONAL JOURNAL OF BIOPRINTING
IF6
err2024-08-05
err18
errOAAI
errBehbehani, Mehri; Glen, Adam; Taylor, Caroline S.; Schuhmacher, Alexander; Claeyssens, Frederik; Haycock, John W.
err分享
err收藏
Is the blockbuster imperative broken
errDRUG DISCOVERY TODAY
IF7.5
err2023-11-01
err1
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Boger, Nikolaj; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
Analysis of pharma R&D productivity - a new perspective needed制药研发生产率分析 -- 需要一个新的视角
errDRUG DISCOVERY TODAY
IF7.5
err2023-10-01
err26
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Stein, Alexander von Stegmann und; Hartl, Dominik; Gassmann, Oliver
err分享
err收藏
Investigating the origins of recent pharmaceutical innovation
errNATURE REVIEWS DRUG DISCOVERY
IF101.8
err2023-07-05
err9
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Dodel, Alexander; Gassmann, Oliver; Hartl, Dominik
err分享
err收藏
The dominant logic of Big Tech in healthcare and pharma医疗保健和制药领域大技术的主导逻辑
errDRUG DISCOVERY TODAY
IF7.5
err2023-02-01
err7
PREAI
errSchuhmacher, Alexander; Haefner, Naomi; Honsberg, Katharina; Goldhahn, Jorg; Gassmann, Oliver
err分享
err收藏
The significance of blockbusters in the pharmaceutical industry
errNATURE REVIEWS DRUG DISCOVERY
IF101.8
err2022-12-12
err9
PREAI
errSchuhmacher, Alexander; Hinder, Markus; Boger, Nikolaj; Hartl, Dominik; Gassmann, Oliver
err分享
err收藏
Open innovation: A paradigm shift in pharma R&D?
errDRUG DISCOVERY TODAY
IF7.5
err2022-09-01
err24
PREAI
errSchuhmacher, Alexander; Gassmann, Oliver; Bieniok, Doria; Hinder, Markus; Hartl, Dominik
err分享
err收藏
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
errDRUG DISCOVERY TODAY
IF7.5
err2021-12-01
err7
PREAI
errSchuhmacher, Alexander; Brieke, Clara; Gassmann, Oliver; Hinder, Markus; Hartl, Dominik
err分享
err收藏
Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence医药研发领域的大科技与初创企业 -- 人工智能的2020视角
errDRUG DISCOVERY TODAY
IF7.5
err2021-10-01
err12
PREAI
errSchuhmacher, Alexander; Gatto, Alexander; Kuss, Michael; Gassmann, Oliver; Hinder, Markus
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
R
Richard W. Siegel
H 指数: 81 · 论文数: 382
J
John W. Haycock
H 指数: 73 · 论文数: 285
O
Oliver Gassmann
H 指数: 69 · 论文数: 1.0K
D
Dominik Hartl
H 指数: 67 · 论文数: 263
R
Ronald E. Law
H 指数: 52 · 论文数: 156
查看更多